Can MTHFR C677T and A1298C Polymorphisms Alter the Risk and Severity of Sporadic Breast Cancer in Brazilian Women?

Rezende, Lúciana Montes; Marson, Fernando Augusto Lima; Lima, Carmen Sílvia Passos; Bertuzzo, Carmen Sílvia

doi:10.1016/j.clbc.2017.02.004

Cited by 11 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings of haplotype analysis among Egyptian females also clarified that the most frequent haplotype of the two loci of MTHFR (rs1801133-rs1801131) is TC which was significantly associated with dual negativity of both ER and PR hormones, overexpression of HER2neu, lymph node metastasis and tumor size. These findings are evidenced by earlier reports (Rezende et al, 2017;Castigilia et al, 2019). However, there was no correlation of our data with age or disease onset.…”

Section: Discussionsupporting

confidence: 82%

Strong Correlation of MTHFR Gene Polymorphisms with Breast Cancer and its Prognostic Clinical Factors among Egyptian Females

Omran

Fotouh

Shousha

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

Strong Correlation of MTHFR Gene Polymorphisms with Breast Cancer and its Prognostic Clinical Factors among Egyptian Females

Omran

Fotouh

Shousha

et al. 2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

“…Numerous studies have been undertaken to assess the influence of the C677T polymorphism of MTHFR in breast cancer, but the conclusions remain conflicted. Our results are consistent with previously published work, which found no significant association with risk of breast cancer [ 27 – 29 , 31 , 33 ]. Three recent meta-analyses, one comprising 75 studies with 31,315 cases and 35, 608 controls, the second comprising 39 studies with 19,260 cases and 26,364 controls, and the third comprising 67 studies with 23,440 cases and 27880 controls, showed no significant association between the C677T polymorphism of MTHFR and risk of breast cancer in Caucasian women, but not in Asian women [ 19 , 20 , 34 ] and mixed women population [ 34 ].…”

Section: Discussionsupporting

confidence: 94%

“…We observed that the frequency of the mutant T allele in our healthy controls (5.0%) was statistically comparable to those reported in West African countries, including, Burkina Faso (6.0%) [22], Nigeria (6%) [23], Gambia (6.2%) [24], Togo (8.3%) [25], and Ghana (8%) [26]. In contrast, this frequency was lower than those observed in India (13.1%) [27], Morocco (24.0%) [14], Iran (21.7%) [21], Turkey (27.4%) [28], Brazil (31.2%) [29], United States of America (31.5%) [30], Italy (41.4%) [31], China (41.8%) [32], and Mexico (43.2%) [33]. Te wide range distribution of the mutant T allele in healthy women appears to depend on the study population and ethnic origins.…”

Section: Discussionmentioning

confidence: 81%

Lack of Association of C677T Methylenetetrahydrofolate Reductase Polymorphism with Breast Cancer Risk in Mali

et al. 2023

View full text Add to dashboard Cite

Methylenetetrahydrofolate reductase (MTHFR) plays a major role in the metabolism of folates and homocysteine, which in turn can affect gene expression and ultimately promote the development of breast cancer. Thus, mutations in the MTHFR gene could influence homocysteine, methionine, and S-adenosylmethionine levels and, indirectly, nucleotide levels. Imbalance in methionine and S-adenosylmethionine synthesis affects protein synthesis and methylation. These changes, which affect gene expression, may ultimately promote the development of breast cancer. We therefore hypothesized that such mutations could also play an important role in the occurrence and pathogenesis of breast cancer in a Malian population. In this study, we used the PCR-RFLP technique to identify the different genotypic profiles of the C677T MTHFR polymorphism in 127 breast cancer women and 160 healthy controls. The genotypic distribution of the C677T polymorphism in breast cancer cases was 88.2% for CC, 11.0% for CT, and 0.8% for TT. Healthy controls showed a similar distribution with 90.6% for CC, 8.8% for CT, and 0.6% for TT. We found no statistical association between the C677T polymorphism and breast cancer risk for the codominant models CT and TT p > 0.05 . The same trend was observed when the analysis was extended to other genetic models, including dominant (p = 0.50), recessive (p = 0.87), and additive (p = 0.50) models. The C677T polymorphism of MTHFR gene did not influence the risk of breast cancer in the Malian samples.

show abstract

“…The higher risk of breast cancer in postmenopausal women than the premenopausal women could be results from difference in the expression of estrogen receptor in the first group and there might be estrogen receptor gene misregulation in the presence of MTHFR 677TT genotype (8). Among Brazilian women, although the MTHFR C677T polymorphism was not associated with the risk of breast cancer, but it was related to clinical severity of the disease (23). The inconsistent findings of association between the MTHFR C677T and breast cancer risk in different populations may underlie ethnic differences, different lifestyle, and disease prevalence as well as possible limitations due to the relatively small sample size.…”

Section: Discussionmentioning

confidence: 94%

MTHFR C677T Polymorphism Is Associated with the Risk of Breast Cancer among Kurdish Population from Western Iran

et al. 2019

View full text Add to dashboard Cite

Background: The key enzyme of methylenetetrahydrofolate reductase (MTHFR) is involved in DNA biosynthesis and repair. Objectives: The role of MTHFR C677T polymorphism in susceptibility to breast cancer is controversial. Methods: In the present case-control investigation, 297 individuals consisted of 100 patients with breast cancer and 197 healthy women were studied for MTHFR C677T genotypes, using PCR-RFLP method. Results: The frequency of MTHFR TT genotype was 10% in patients and 3% in controls (P = 0.008). The presence of TT genotype was associated with susceptibility to breast cancer [OR = 1.97, 95%CI: 1.16-3.36, P = 0.012]. The T allele of MTHFR was found in 30% of the patients compared to 27.6% healthy controls (P = 0.024) that enhanced the risk of breast cancer by 1.56 times (95% CI: 1.06-2.3, P = 0.024). There were 71 individuals (71%) with the age of breast cancer diagnosis ≤ 51 years old. Comparing patients with the age of cancer diagnosis ≤ 50 years old with those > 51 years old group indicated a higher frequency of MTHFR TT genotype in the latter (20.7%) compared to the first group (5.6%, P = 0.05). Conclusions: Our study demonstrated an association between the MTHFR C677T polymorphism with the risk of breast cancer among population of Western Iran. Also, our study suggests that the MTHFR TT genotype could be a risk factor for breast cancer in postmenopausal women.

show abstract

Can MTHFR C677T and A1298C Polymorphisms Alter the Risk and Severity of Sporadic Breast Cancer in Brazilian Women?

Cited by 11 publications

References 46 publications

Strong Correlation of MTHFR Gene Polymorphisms with Breast Cancer and its Prognostic Clinical Factors among Egyptian Females

Strong Correlation of MTHFR Gene Polymorphisms with Breast Cancer and its Prognostic Clinical Factors among Egyptian Females

Lack of Association of C677T Methylenetetrahydrofolate Reductase Polymorphism with Breast Cancer Risk in Mali

MTHFR C677T Polymorphism Is Associated with the Risk of Breast Cancer among Kurdish Population from Western Iran

Contact Info

Product

Resources

About